Pyxis Oncology, Inc. (PYXS)
- Previous Close
4.1600 - Open
4.2200 - Bid 4.5000 x 300
- Ask 4.5500 x 500
- Day's Range
4.1600 - 4.6900 - 52 Week Range
1.3500 - 6.8500 - Volume
470,229 - Avg. Volume
914,216 - Market Cap (intraday)
263.344M - Beta (5Y Monthly) 1.51
- PE Ratio (TTM)
-- - EPS (TTM)
-1.8500 - Earnings Date May 11, 2024 - May 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.00
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
www.pyxisoncology.comRecent News: PYXS
Performance Overview: PYXS
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PYXS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PYXS
Valuation Measures
Market Cap
263.34M
Enterprise Value
165.38M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.09
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.06
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.10%
Return on Equity (ttm)
-51.51%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-73.79M
Diluted EPS (ttm)
-1.8500
Balance Sheet and Cash Flow
Total Cash (mrq)
119.3M
Total Debt/Equity (mrq)
16.97%
Levered Free Cash Flow (ttm)
-43.21M